Kunizaki Masaki, Hamasaki Keiko, Wakata Kouki, Hidaka Shigekazu, Nagayasu Takeshi, Kinoshita Yukie
Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Clin J Gastroenterol. 2017 Dec;10(6):503-507. doi: 10.1007/s12328-017-0780-x. Epub 2017 Sep 26.
Serum tumor markers in patients with cancer assist with establishing diagnosis, estimating prognosis, monitoring treatment, and detecting tumor recurrence. Changes in the p53 tumor suppressor gene are the most common genetic abnormalities in many different human malignancies. Several studies have demonstrated that serum p53 antibodies (S-p53Ab) comprise an early marker of malignant disease, a marker for treatment effects and a prognostic factor for patients with several types of tumors. We recently reported that S-p53Ab is useful for patients with gastric cancer. We describe a rare situation in which unusually high serum p53 antibodies helped to detect recurrent gastric cancer in the small intestine after gastrectomy. Further studies are required to gain a more precise understanding of the clinical impact of S-p53Ab titer monitoring in gastric cancer.
癌症患者的血清肿瘤标志物有助于确诊、评估预后、监测治疗以及检测肿瘤复发。p53肿瘤抑制基因的改变是许多不同人类恶性肿瘤中最常见的基因异常。多项研究表明,血清p53抗体(S-p53Ab)是恶性疾病的早期标志物、治疗效果的标志物以及几种肿瘤患者的预后因素。我们最近报道S-p53Ab对胃癌患者有用。我们描述了一种罕见情况,即异常高的血清p53抗体有助于检测胃癌切除术后小肠中的复发性胃癌。需要进一步研究以更精确地了解S-p53Ab滴度监测对胃癌的临床影响。